AbbVie’s purchase of Allergan expands patent scope

The acquisition is a play by the Illinois-based pharma giant to mitigate the impact of losing exclusivity of Humira, but it also gives it strength in underrepresented areas of its portfolio

Get unlimited access to all IAM content